Drug General Information (ID: DDIV1PN3Q9)
Drug Name			Eltrombopag		Drug Info		Iron protein succinylate		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Platelet-Stimulating Agents				Iron Supplement

Mechanism of Eltrombopag-Iron protein succinylate Interaction (Severity Level: Moderate)
Complex formation Click to Show/Hide Mechanism Graph
Drug Name		Eltrombopag				Iron protein succinylate
Mechanism		Binds to polyvalent cations				Polyvalent cations
Key Mechanism Factor 1
		Factor Name		Chelation
		Factor Description		Chelation is a direct drug interaction that usually involves the formation of dimers or trimers, resulting in larger complexes and poorer absorption.
Mechanism Description		Decreased absorption of Iron protein succinylate due to formation of complexes caused by Eltrombopag

Recommended Action
Management		Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution), aluminum, calcium, iron, magnesium, zinc or other polyvalent cations.

References
1	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
2	Product Information. Promacta (eltrombopag). GlaxoSmithKline, Research Triangle Park, NC.